HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4991W93

a 5HT(1B/1D) receptor partial agonist; inhibits electrically induced plasma extravasation; structure in first source

Also Known As:

4-(3-(3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl)oxazolidin-2-one

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - 4991W93: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 4991W93: 1

Experts

1.	Edvinsson, L: 1 article (03/2001)
2.	Goadsby, P J: 1 article (03/2001)
3.	Knight, Y E: 1 article (03/2001)

Related Diseases

1.

Migraine Disorders (Migraine)

03/01/2001 - "Given that 4991W93 is inactive clinically at non-vascular doses, it seems clear that the 5HT(1B/1D) agonist effects of the compound are necessary for blockade of CGRP release and thus any anti-migraine action. "
03/01/2001 - "4991W93, a conformationally restricted analogue of zolmitriptan, is also a potent inhibitor of PPE at doses without 5HT(1B/1D)-mediated effects, that was developed as an anti-migraine drug, and thus was suitable to test whether higher doses of such conformationally restricted triptan analogues could inhibit trigeminal-evoked CGRP release. "

Related Drugs and Biologics

1.	Tryptamines (Triptans)
2.	zolmitriptan (Zomig)